# Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate

> **NCT06730516** · EARLY_PHASE1 · COMPLETED · sponsor: **Zagazig University** · enrollment: 56 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Latanoprost (Xalatan)
- **DRUG:** Brimonidine 0.2 %

## Key facts

- **NCT ID:** NCT06730516
- **Lead sponsor:** Zagazig University
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-24
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06730516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06730516, "Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06730516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*